Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
KOSECOFF JACQUELINE B
  2. Issuer Name and Ticker or Trading Symbol
Steris plc [STE]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O CHANCERY HOUSE, 190 WATERSIDE ROAD, HAMILTON INDUSTRIAL PARK
3. Date of Earliest Transaction (Month/Day/Year)
11/02/2015
(Street)

LEICESTER, X0 LE5 1QZ
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, ?0.10 Nominal Value 11/02/2015   A   29,785 A (1) 29,785 D  
Ordinary Shares, ?0.10 Nominal Value 11/02/2015   A   9,063 A (1) 9,063 I See Footnote Below. (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (right to buy) $ 27.68 11/02/2015   A   3,387     (3) 07/27/2017 Ordinary Shares, ?0.10 Nominal Value 3,387 (3) 3,387 D  
Director Stock Option (right to buy) $ 34.17 11/02/2015   A   2,744     (4) 07/31/2018 Ordinary Shares, ?0.10 Nominal Value 2,744 (4) 2,744 D  
Director Stock Option (right to buy) $ 28.08 11/02/2015   A   3,609     (5) 07/31/2019 Ordinary Shares, ?0.10 Nominal Value 3,609 (5) 3,609 D  
Director Stock Option (right to buy) $ 32.34 11/02/2015   A   3,133     (6) 08/04/2020 Ordinary Shares, ?0.10 Nominal Value 3,133 (6) 3,133 D  
Director Stock Option (right to buy) $ 31.61 11/02/2015   A   3,121     (7) 08/03/2021 Ordinary Shares, ?0.10 Nominal Value 3,121 (7) 3,121 D  
Director Stock Option (right to buy) $ 32.36 11/02/2015   A   3,218     (8) 08/03/2022 Ordinary Shares, ?0.10 Nominal Value 3,218 (8) 3,218 D  
Director Stock Option (right to buy) $ 43.92 11/02/2015   A   4,657     (9) 08/08/2023 Ordinary Shares, ?0.10 Nominal Value 4,657 (9) 4,657 D  
Director Stock Option (right to buy) $ 51.53 11/02/2015   A   4,584     (10) 08/06/2024 Ordinary Shares, ?0.10 Nominal Value 4,584 (10) 4,584 D  
Director Stock Option (right to buy) $ 64.05 11/02/2015   A   4,110     (11) 08/31/2025 Ordinary Shares, ?0.10 Nominal Value 4,110 (11) 4,110 D  
Career Restricted Stock Units (12) 11/02/2015   A   2,845     (12)   (12) Ordinary Shares, ?0.10 Nominal Value 2,845 $ 0 2,845 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
KOSECOFF JACQUELINE B
C/O CHANCERY HOUSE, 190 WATERSIDE ROAD
HAMILTON INDUSTRIAL PARK
LEICESTER, X0 LE5 1QZ
  X      

Signatures

 /s/ Dennis P. Patton, Authorized Representative under Power of Attorney   11/02/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents ordinary shares of STERIS plc ("New STERIS") acquired pursuant to merger of a wholly-owned subsidiary of New STERIS with and into STERIS Corporation ("STERIS"), with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for common shares of STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.
(2) These ordinary shares are held in a revocable family trust of the Reporting Person and the Reporting Person's spouse, as Co-Trustees.
(3) This option to purchase 3,387 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 3,387 STERIS common shares for $27.68 per share, subject to the same terms and conditions as the original STERIS stock option.
(4) This option to purchase 2,744 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 2,744 STERIS common shares for $34.17 per share, subject to the same terms and conditions as the original STERIS stock option.
(5) This option to purchase 3,609 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 3,609 STERIS common shares for $28.08 per share, subject to the same terms and conditions as the original STERIS stock option.
(6) This option to purchase 3,133 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 3,133 STERIS common shares for $32.34 per share, subject to the same terms and conditions as the original STERIS stock option.
(7) This option to purchase 3,121 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 3,121 STERIS common shares for $31.61 per share, subject to the same terms and conditions as the original STERIS stock option.
(8) This option to purchase 3,218 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 3,218 STERIS common shares for $32.36 per share, subject to the same terms and conditions as the original STERIS stock option.
(9) This option to purchase 4,657 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,657 STERIS common shares for $43.92 per share, subject to the same terms and conditions as the original STERIS stock option.
(10) This option to purchase 4,584 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,584 STERIS common shares for $51.53 per share, subject to the same terms and conditions as the original STERIS stock option.
(11) This option to purchase 4,110 New STERIS ordinary shares, which is fully vested, was received in the Merger in exchange for an option to purchase 4,110 STERIS common shares for $64.05 per share, subject to the same terms and conditions as the original STERIS stock option.
(12) At the effective time of the Merger, each STERIS career restricted stock unit was cancelled and converted to a New STERIS career restricted stock unit, subject to the same terms and conditions that were applicable to the original STERIS career restricted stock unit. These New STERIS career restricted stock units are fully vested and will be settled in New STERIS ordinary shares six months after the cessation of the Director's Board service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.